anavex3-71
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 3, 2020 (NCT04442945)
Timeline
Indications
Mechanism of action
- Sigma opioid receptorINHIBITOR
SIGMAR1 inhibitor
- Muscarinic acetylcholine receptor M1INHIBITOR
CHRM1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06245213 | Phase 2 | Mar 15, 2024 | Anavex Life Sciences Corp., COGNISION, Cognitive Research Corporation, Hassman Research Institute |
| NCT04442945 | Phase 1 | Jul 3, 2020 | Anavex Life Sciences Corp. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp. | For profit | 2 | 2 | 2 | 2020 |
| COGNISION | For profit | 1 | 0 | 1 | 2024 |
| Cognitive Research Corporation | For profit | 1 | 0 | 1 | 2024 |
| Hassman Research Institute | For profit | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1